Calamos Advisors’s LB Pharmaceuticals LBRX Stock Holding History

Calamos Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$593K	Buy	+24,063	New	+$555K	﹤0.01%	883

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Calamos Advisors's LBRX Position: Q1 2026 in Review

Calamos Advisors opened a new position in LB Pharmaceuticals (LBRX) in Q1 2026: 24,063 shares worth $593K. The stake represents ﹤0.01% of the portfolio and ranks #883 among its holdings.

77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Calamos Advisors held 24,063 shares of LB Pharmaceuticals worth $593K as of Q1 2026.
LB Pharmaceuticals was a new Calamos Advisors position in Q1 2026.
LB Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #883 holding.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.